Estrella Immunopharma Inc... (ESLA)
NASDAQ: ESLA
· Real-Time Price · USD
0.89
-0.04 (-4.35%)
At close: Jun 26, 2025, 3:59 PM
0.90
1.03%
After-hours: Jun 26, 2025, 03:59 PM EDT
Company Description
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States.
The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.
It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.
Estrella Immunopharma, Inc. is based in EmeryVille, California.
Estrella Immunopharma Inc.
| Country | United States |
| IPO Date | Sep 14, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | n/a |
| CEO | Cheng Liu |
Contact Details
Address: 5858 Horton Street EmeryVille, California United States | |
| Website | https://www.estrellabio.com |
Stock Details
| Ticker Symbol | ESLA |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001844417 |
| CUSIP Number | 297584104 |
| ISIN Number | US2975841048 |
| Employer ID | 00-0000000 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Dr. Cheng Liu Ph.D. | Chief Executive Officer, President & Director |
| Jiandong Xu | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 05, 2025 | 8-K | Current Report |
| Jun 03, 2025 | 8-K | Current Report |
| May 29, 2025 | 8-K | Current Report |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 02, 2025 | 8-K | Current Report |
| Mar 25, 2025 | 10-KT | Filing |
| Feb 21, 2025 | 8-K | Current Report |
| Feb 20, 2025 | 8-K | Current Report |
| Feb 14, 2025 | 4 | Filing |
| Feb 14, 2025 | 4 | Filing |